Pearce IP BioBlast: w/e 14 Feb 2020

• On 11 February 2020, Amgen sued Hospira in the District Court of Delaware, alleging Hospira's aBLA for a proposed pegfilgrastim biosimilar infringes Amgen's Neulasta patent for protein purification (no. 8,273,707).